Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from ASCO

 

• Abstract published online in the Journal of Clinical Oncology supplement of the 2023 ASCO Annual Meeting Proceedings
• Can-Fite to initiate Phase 2a pancreatic cancer study
• Namodenoson significantly inhibits growth of pancreatic carcinoma as a stand-alone treatment and in combination with gemcitabine

https://www.biospace.com/article/releases/can-fite-namodenoson-s-inhibition-of-pancreatic-carcinoma-receives-recognition-from-the-american-society-of-clinical-oncology-asco-/